FAP, June 1 / PRNewswire-Asianet /-- the US Food and Drug Administration (FDA) approved Pfizer's respiratory syncytial virus vaccine Abrysvo. Pfizer expects the vaccine to be officially available in the third quarter of 2023. (Bloomberg)